Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

OncoMed Loses Another Asset – Rosmantuzumab – And CEO Paul Hastings

Jan 05 2018

Glass broken cracks splinters

Related Content

Celgene pays $177 million for cancer stem cell pact with OncoMed

Dec 04 2013

Finance Watch: OncoMed Cuts Costs To Conserve Capital While Public, Private Peers Raise Cash

May 01 2017

Related Companies

OncoMed Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Bayer AG

GSK plc

Additional Topics

Clinical Trials Research & Development Cancer BioPharmaceutical

More from Anticancer

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window